Revelation Biosciences REVB
NASDAQ REVB
$0.83 -0.03 (-3.64%)
As of: Sep 29, 2026 · 3:59 PM EDT

Revelation Biosciences (REVB) Total Debt (2020 - 2021)

Updated

Revelation Biosciences (REVB) reported Total Debt of $774,345 for Q4 2021.

Analysis

Revelation Biosciences (REVB) Total Debt (2020 - 2021) Analysis & Trends

  • The Q4 2021 figure ranks as the lowest quarterly Total Debt since Q3 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 49.04 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 70.82 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 53.91 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 37.49 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -111.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 57.30 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 26.25 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 63.19 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Revelation Biosciences 3.36 Mn -45.66 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 774,345.00
Sep 30, 2020 125,000.00
API Access

Revelation Biosciences Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=REVB&period=max&api_key=YOUR_API_KEY